A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis



Study Arms

  • Experimental: SQ109 75 mg
  • Experimental: SQ109 150 mg
  • Experimental: SQ109 300 mg
  • Experimental: SQ109 150 mg + RIF
  • Experimental: SQ109 300 mg + RIF
  • Active Comparator: RIF Mono

Primary Outcome Measures

The extended early bactericidal activity (EBA) of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.